ID FSHR_HUMAN Reviewed; 695 AA. AC P23945; A0A0A0MSC5; A8K947; G5CBS7; G5E967; J3KQ00; Q05AH0; Q16225; Q4QRJ3; AC Q4ZFZ2; Q53RW2; DT 01-MAR-1992, integrated into UniProtKB/Swiss-Prot. DT 02-NOV-2010, sequence version 3. DT 24-JAN-2024, entry version 235. DE RecName: Full=Follicle-stimulating hormone receptor; DE Short=FSH-R; DE AltName: Full=Follitropin receptor; DE Flags: Precursor; GN Name=FSHR; Synonyms=LGR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT SER-680. RC TISSUE=Ovary; RX PubMed=1709010; DOI=10.1016/0006-291x(91)91682-3; RA Minegish T., Nakamura K., Takakura Y., Ibuki Y., Igarashi M.; RT "Cloning and sequencing of human FSH receptor cDNA."; RL Biochem. Biophys. Res. Commun. 175:1125-1130(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT THR-307. RX PubMed=1322283; DOI=10.1210/endo.131.2.1322283; RA Tilly J.L., Aihara T., Nishimori K., Jia X.-C., Billig H., Kowalski K.I., RA Perlas E.A., Hsueh A.J.; RT "Expression of recombinant human follicle-stimulating hormone receptor: RT species-specific ligand binding, signal transduction, and identification of RT multiple ovarian messenger ribonucleic acid transcripts."; RL Endocrinology 131:799-806(1992). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT THR-307. RC TISSUE=Testis; RX PubMed=1301382; DOI=10.1016/0303-7207(92)90220-z; RA Kelton C.A., Cheng S.V., Nugent N.P., Schweickhardt R.L., Rosenthal J.L., RA Overton S.A., Wands G.D., Kuzeja J.B., Luchette C.A., Chappel S.C.; RT "The cloning of the human follicle stimulating hormone receptor and its RT expression in COS-7, CHO, and Y-1 cells."; RL Mol. Cell. Endocrinol. 89:141-151(1992). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG). RC TISSUE=Adipose tissue; RA Liu X., Huang H., Sheng J.; RT "FSHR expression in adipose tissue."; RL Submitted (MAY-2011) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG), AND VARIANT THR-307. RC TISSUE=Testis; RA Kopatz S.A., Aronstam R.S., Sharma S.V.; RT "cDNA clones of human proteins involved in signal transduction sequenced by RT the Guthrie cDNA resource center (www.cdna.org)."; RL Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG), AND VARIANT THR-307. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT SER-680. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT SER-680. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LONG AND 3), AND VARIANTS RP THR-307 AND SER-680. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-342 (ISOFORM SHORT), AND VARIANT THR-307. RC TISSUE=Testis; RX PubMed=1359889; DOI=10.1016/0006-291x(92)91341-m; RA Gromoll J., Gudermann T., Nieschlag E.; RT "Molecular cloning of a truncated isoform of the human follicle stimulating RT hormone receptor."; RL Biochem. Biophys. Res. Commun. 188:1077-1083(1992). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-51. RX PubMed=7926278; DOI=10.1016/0303-7207(94)90102-3; RA Gromoll J., Dankbar B., Gudermann T.; RT "Characterization of the 5' flanking region of the human follicle- RT stimulating hormone receptor gene."; RL Mol. Cell. Endocrinol. 102:93-102(1994). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 286-695, AND VARIANTS THR-307 AND RP SER-680. RX PubMed=7916967; DOI=10.1677/jme.0.0120265; RA Gromoll J., Ried T., Holtgreve-Grez H., Nieschlag E., Gudermann T.; RT "Localization of the human FSH receptor to chromosome 2p21 using a genomic RT probe comprising exon 10."; RL J. Mol. Endocrinol. 12:265-271(1994). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, SULFATION AT TYR-335, AND MUTAGENESIS OF RP TYR-330 AND TYR-335. RX PubMed=11847099; DOI=10.1093/emboj/21.4.504; RA Costagliola S., Panneels V., Bonomi M., Koch J., Many M.C., Smits G., RA Vassart G.; RT "Tyrosine sulfation is required for agonist recognition by glycoprotein RT hormone receptors."; RL EMBO J. 21:504-513(2002). RN [14] RP ALTERNATIVE SPLICING (ISOFORM 4). RX PubMed=11872202; DOI=10.1016/s0015-0282(01)03221-6; RA Song G.J., Park Y.S., Lee Y.S., Lee C.C., Kang I.S.; RT "Alternatively spliced variants of the follicle-stimulating hormone RT receptor gene in the testis of infertile men."; RL Fertil. Steril. 77:499-504(2002). RN [15] RP INTERACTION WITH APPL2. RX PubMed=17030088; DOI=10.1016/j.mce.2006.08.014; RA Nechamen C.A., Thomas R.M., Dias J.A.; RT "APPL1, APPL2, Akt2 and FOXO1a interact with FSHR in a potential signaling RT complex."; RL Mol. Cell. Endocrinol. 260:93-99(2007). RN [16] RP 3D-STRUCTURE MODELING OF 49-228. RX PubMed=8747461; DOI=10.1016/s0969-2126(01)00272-6; RA Jiang X., Dreano M., Buckler D.R., Cheng S., Ythier A., Wu H., RA Hendrickson W.A., el Tayar N.; RT "Structural predictions for the ligand-binding region of glycoprotein RT hormone receptors and the nature of hormone-receptor interactions."; RL Structure 3:1341-1353(1995). RN [17] RP X-RAY CRYSTALLOGRAPHY (2.92 ANGSTROMS) OF 17-268 IN COMPLEX WITH FSHA AND RP FSHB, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-191. RX PubMed=15662415; DOI=10.1038/nature03206; RA Fan Q.R., Hendrickson W.A.; RT "Structure of human follicle-stimulating hormone in complex with its RT receptor."; RL Nature 433:269-277(2005). RN [18] {ECO:0007744|PDB:4MQW} RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 16-366 OF HOMOTRIMER IN COMPLEX RP WITH CGA AND FSHB, FUNCTION, SUBCELLULAR LOCATION, GLYCOSYLATION AT RP ASN-191, AND DISULFIDE BONDS. RX PubMed=24692546; DOI=10.1074/jbc.m114.549592; RA Jiang X., Fischer D., Chen X., McKenna S.D., Liu H., Sriraman V., Yu H.N., RA Goutopoulos A., Arkinstall S., He X.; RT "Evidence for follicle-stimulating hormone receptor as a functional RT trimer."; RL J. Biol. Chem. 289:14273-14282(2014). RN [19] RP VARIANT ODG1 VAL-189. RX PubMed=7553856; DOI=10.1016/0092-8674(95)90275-9; RA Aittomaeki K., Lucena J.L.D., Pakarinen P., Sistonen P., Tapanainen J., RA Gromoll J., Kaskikari R., Sankila E.-M., Lehvaslaiho H., Engel A.R., RA Nieschlag E., Huhtaniemi I., de la Chapelle A.; RT "Mutation in the follicle-stimulating hormone receptor gene causes RT hereditary hypergonadotropic ovarian failure."; RL Cell 82:959-968(1995). RN [20] RP VARIANT OVARIAN SEX CORD TUMOR SER-591. RX PubMed=9100567; DOI=10.1210/jcem.82.4.3870; RA Kotlar T.J., Young R.H., Albanese C., Crowley W.F. Jr., Scully R.E., RA Jameson J.L.; RT "A mutation in the follicle-stimulating hormone receptor occurs frequently RT in human ovarian sex cord tumors."; RL J. Clin. Endocrinol. Metab. 82:1020-1026(1997). RN [21] RP VARIANT FSHR ACTIVATION GLY-567, AND CHARACTERIZATION OF VARIANT FSHR RP ACTIVATION GLY-567. RX PubMed=8636335; DOI=10.1210/jcem.81.4.8636335; RA Gromoll J., Simoni M., Nieschlag E.; RT "An activating mutation of the follicle-stimulating hormone receptor RT autonomously sustains spermatogenesis in a hypophysectomized man."; RL J. Clin. Endocrinol. Metab. 81:1367-1370(1996). RN [22] RP VARIANT ODG1 VAL-189. RX PubMed=9851774; DOI=10.1210/jcem.83.12.5306; RA Jiang M., Aittomaeki K., Nilsson C., Pakarinen P., Iitia A., Torresani T., RA Simonsen H., Goh V., Pettersson K., de la Chapelle A., Huhtaniemi I.; RT "The frequency of an inactivating point mutation (566C-->T) of the human RT follicle-stimulating hormone receptor gene in four populations using RT allele-specific hybridization and time-resolved fluorometry."; RL J. Clin. Endocrinol. Metab. 83:4338-4343(1998). RN [23] RP VARIANTS ODG1 THR-160 AND CYS-573. RX PubMed=9769327; DOI=10.1172/jci3795; RA Beau I., Touraine P., Meduri G., Gougeon A., Desroches A., Matuchansky C., RA Milgrom E., Kuttenn F., Misrahi M.; RT "A novel phenotype related to partial loss of function mutations of the RT follicle stimulating hormone receptor."; RL J. Clin. Invest. 102:1352-1359(1998). RN [24] RP VARIANTS ODG1 VAL-224 AND VAL-601, AND CHARACTERIZATION OF VARIANTS ODG1 RP VAL-224; CYS-573 AND VAL-601. RX PubMed=10551778; DOI=10.1210/mend.13.11.0370; RA Touraine P., Beau I., Gougeon A., Meduri G., Desroches A., Pichard C., RA Detoeuf M., Paniel B., Prieur M., Zorn J.-R., Milgrom E., Kuttenn F., RA Misrahi M.; RT "New natural inactivating mutations of the follicle-stimulating hormone RT receptor: correlations between receptor function and phenotype."; RL Mol. Endocrinol. 13:1844-1854(1999). RN [25] RP VARIANTS THR-307; ARG-524 AND SER-680. RX PubMed=10391209; DOI=10.1038/10290; RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., RA Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., RA Lander E.S.; RT "Characterization of single-nucleotide polymorphisms in coding regions of RT human genes."; RL Nat. Genet. 22:231-238(1999). RN [26] RP ERRATUM OF PUBMED:10391209. RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., RA Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., RA Lander E.S.; RL Nat. Genet. 23:373-373(1999). RN [27] RP VARIANTS THR-307 AND SER-680. RX PubMed=12059813; DOI=10.1046/j.1439-0272.2002.00493.x; RA Asatiani K., Gromoll J., Eckardstein S.V., Zitzmann M., Nieschlag E., RA Simoni M.; RT "Distribution and function of FSH receptor genetic variants in normal RT men."; RL Andrologia 34:172-176(2002). RN [28] RP VARIANT ODG1 THR-419, AND CHARACTERIZATION OF VARIANT ODG1 THR-419. RX PubMed=11889179; DOI=10.1210/jcem.87.3.8319; RA Doherty E., Pakarinen P., Tiitinen A., Kiilavuori A., Huhtaniemi I., RA Forrest S., Aittomaeki K.; RT "A novel mutation in the FSH receptor inhibiting signal transduction and RT causing primary ovarian failure."; RL J. Clin. Endocrinol. Metab. 87:1151-1155(2002). RN [29] RP VARIANT ODG1 ARG-348. RX PubMed=12571157; DOI=10.1093/humrep/deg046; RA Allen L.A., Achermann J.C., Pakarinen P., Kotlar T.J., Huhtaniemi I.T., RA Jameson J.L., Cheetham T.D., Ball S.G.; RT "A novel loss of function mutation in exon 10 of the FSH receptor gene RT causing hypergonadotrophic hypogonadism: clinical and molecular RT characteristics."; RL Hum. Reprod. 18:251-256(2003). RN [30] RP VARIANT ODG1 THR-519, AND CHARACTERIZATION OF VARIANT ODG1 THR-519. RX PubMed=12915623; DOI=10.1210/jc.2003-030217; RA Meduri G., Touraine P., Beau I., Lahuna O., Desroches A., RA Vacher-Lavenu M.C., Kuttenn F., Misrahi M.; RT "Delayed puberty and primary amenorrhea associated with a novel mutation of RT the human follicle-stimulating hormone receptor: clinical, histological, RT and molecular studies."; RL J. Clin. Endocrinol. Metab. 88:3491-3498(2003). RN [31] RP VARIANT OHSS ILE-449. RX PubMed=12930927; DOI=10.1056/nejmoa030065; RA Vasseur C., Rodien P., Beau I., Desroches A., Gerard C., de Poncheville L., RA Chaplot S., Savagner F., Croue A., Mathieu E., Lahlou N., Descamps P., RA Misrahi M.; RT "A chorionic gonadotropin-sensitive mutation in the follicle-stimulating RT hormone receptor as a cause of familial gestational spontaneous ovarian RT hyperstimulation syndrome."; RL N. Engl. J. Med. 349:753-759(2003). RN [32] RP VARIANT OHSS ASN-567. RX PubMed=12930928; DOI=10.1056/nejmoa030064; RA Smits G., Olatunbosun O., Delbaere A., Pierson R., Vassart G., RA Costagliola S.; RT "Ovarian hyperstimulation syndrome due to a mutation in the follicle- RT stimulating hormone receptor."; RL N. Engl. J. Med. 349:760-766(2003). RN [33] RP VARIANT OHSS ALA-449, AND CHARACTERIZATION OF VARIANT OHSS ALA-449. RX PubMed=15080154; DOI=10.1210/jc.2003-031910; RA Montanelli L., Delbaere A., Di Carlo C., Nappi C., Smits G., Vassart G., RA Costagliola S.; RT "A mutation in the follicle-stimulating hormone receptor as a cause of RT familial spontaneous ovarian hyperstimulation syndrome."; RL J. Clin. Endocrinol. Metab. 89:1255-1258(2004). RN [34] RP VARIANT OHSS THR-545, AND CHARACTERIZATION OF VARIANT OHSS THR-545. RX PubMed=16278261; DOI=10.1210/jc.2005-1580; RA De Leener A., Montanelli L., Van Durme J., Chae H., Smits G., Vassart G., RA Costagliola S.; RT "Presence and absence of follicle-stimulating hormone receptor mutations RT provide some insights into spontaneous ovarian hyperstimulation syndrome RT physiopathology."; RL J. Clin. Endocrinol. Metab. 91:555-562(2006). RN [35] RP VARIANT OHSS TYR-128, AND CHARACTERIZATION OF VARIANT OHSS TYR-128. RX PubMed=17721928; DOI=10.1002/humu.20604; RA De Leener A., Caltabiano G., Erkan S., Idil M., Vassart G., Pardo L., RA Costagliola S.; RT "Identification of the first germline mutation in the extracellular domain RT of the follitropin receptor responsible for spontaneous ovarian RT hyperstimulation syndrome."; RL Hum. Mutat. 29:91-98(2008). RN [36] RP VARIANT OHSS ILE-512, CHARACTERIZATION OF VARIANT OHSS ILE-512, AND RP FUNCTION. RX PubMed=24058690; DOI=10.1371/journal.pone.0075478; RA Uchida S., Uchida H., Maruyama T., Kajitani T., Oda H., Miyazaki K., RA Kagami M., Yoshimura Y.; RT "Molecular analysis of a mutated FSH receptor detected in a patient with RT spontaneous ovarian hyperstimulation syndrome."; RL PLoS ONE 8:E75478-E75478(2013). RN [37] RP VARIANTS OHSS ALA-514 AND VAL-575, AND CHARACTERIZATION OF VARIANTS OHSS RP ALA-514 AND VAL-575. RX PubMed=25581598; DOI=10.1210/jc.2014-3662; RA Desai S.S., Achrekar S.K., Sahasrabuddhe K.A., Meharji P.K., Desai S.K., RA Mangoli V.S., Mahale S.D.; RT "Functional characterization of two naturally occurring mutations RT (Val514Ala and Ala575Val) in follicle-stimulating hormone receptor."; RL J. Clin. Endocrinol. Metab. 100:E638-E645(2015). CC -!- FUNCTION: G protein-coupled receptor for follitropin, the follicle- CC stimulating hormone (PubMed:11847099, PubMed:24058690, CC PubMed:24692546). Through cAMP production activates the downstream CC PI3K-AKT and ERK1/ERK2 signaling pathways (PubMed:24058690). CC {ECO:0000269|PubMed:11847099, ECO:0000269|PubMed:24058690, CC ECO:0000269|PubMed:24692546}. CC -!- SUBUNIT: Homotrimer. Functions as a homotrimer binding the FSH hormone CC heterodimer composed of CGA and FSHB (PubMed:24692546). Interacts with CC ARRB2 (By similarity). Interacts with APPL2; interaction is independent CC of follicle stimulating hormone stimulation (PubMed:17030088). CC {ECO:0000250|UniProtKB:P20395, ECO:0000269|PubMed:17030088, CC ECO:0000269|PubMed:24692546}. CC -!- INTERACTION: CC P23945; P27348: YWHAQ; NbExp=4; IntAct=EBI-848239, EBI-359854; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11847099, CC ECO:0000269|PubMed:24692546}; Multi-pass membrane protein CC {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=Long; Synonyms=R1; CC IsoId=P23945-1; Sequence=Displayed; CC Name=Short; Synonyms=E9Del; CC IsoId=P23945-2; Sequence=VSP_001953; CC Name=3; Synonyms=E6Del; CC IsoId=P23945-3; Sequence=VSP_043181; CC Name=4; Synonyms=E8'Inc; CC IsoId=P23945-4; Sequence=VSP_053411; CC -!- TISSUE SPECIFICITY: Sertoli cells and ovarian granulosa cells. CC -!- PTM: Sulfated. {ECO:0000269|PubMed:11847099}. CC -!- PTM: N-glycosylated; indirectly required for FSH-binding, possibly via CC a conformational change that allows high affinity binding of hormone. CC {ECO:0000250|UniProtKB:P20395}. CC -!- DISEASE: Ovarian dysgenesis 1 (ODG1) [MIM:233300]: An autosomal CC recessive disease characterized by primary amenorrhea, variable CC development of secondary sex characteristics, poorly developed streak CC ovaries, and high serum levels of follicle-stimulating hormone (FSH) CC and luteinizing hormone (LH). {ECO:0000269|PubMed:10551778, CC ECO:0000269|PubMed:11889179, ECO:0000269|PubMed:12571157, CC ECO:0000269|PubMed:12915623, ECO:0000269|PubMed:7553856, CC ECO:0000269|PubMed:9769327, ECO:0000269|PubMed:9851774}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Ovarian hyperstimulation syndrome (OHSS) [MIM:608115]: CC Disorder which occurs either spontaneously or most often as an CC iatrogenic complication of ovarian stimulation treatments for in vitro CC fertilization. The clinical manifestations vary from abdominal CC distention and discomfort to potentially life-threatening, massive CC ovarian enlargement and capillary leak with fluid sequestration. CC Pathologic features of this syndrome include the presence of multiple CC serous and hemorrhagic follicular cysts lined by luteinized cells, a CC condition called hyperreactio luteinalis. {ECO:0000269|PubMed:12930927, CC ECO:0000269|PubMed:12930928, ECO:0000269|PubMed:15080154, CC ECO:0000269|PubMed:16278261, ECO:0000269|PubMed:17721928, CC ECO:0000269|PubMed:24058690, ECO:0000269|PubMed:25581598}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. CC FSH/LSH/TSH subfamily. {ECO:0000255|PROSITE-ProRule:PRU00521}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M65085; AAA52477.1; -; mRNA. DR EMBL; M95489; AAA52478.1; -; mRNA. DR EMBL; S59900; AAB26480.1; -; mRNA. DR EMBL; JN003607; AEI86722.1; -; mRNA. DR EMBL; AY429104; AAR07899.1; -; mRNA. DR EMBL; AK292562; BAF85251.1; -; mRNA. DR EMBL; AC007189; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC079394; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC092533; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471053; EAX00188.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00189.1; -; Genomic_DNA. DR EMBL; BC096831; AAH96831.1; -; mRNA. DR EMBL; BC118548; AAI18549.1; -; mRNA. DR EMBL; BC125270; AAI25271.1; -; mRNA. DR EMBL; X68044; CAA48179.1; -; mRNA. DR EMBL; S73199; AAB32071.1; -; Genomic_DNA. DR EMBL; S73526; AAB32225.1; -; Genomic_DNA. DR CCDS; CCDS1843.1; -. [P23945-1] DR CCDS; CCDS1844.2; -. [P23945-3] DR PIR; I57661; QRHUFT. DR RefSeq; NP_000136.2; NM_000145.3. DR RefSeq; NP_852111.2; NM_181446.2. DR PDB; 1XWD; X-ray; 2.92 A; C/F=17-268. DR PDB; 4AY9; X-ray; 2.50 A; X/Y/Z=17-366. DR PDB; 4MQW; X-ray; 2.90 A; X/Y/Z=16-366. DR PDB; 8I2G; EM; 2.80 A; R=18-695. DR PDB; 8I2H; EM; 6.00 A; A=14-695. DR PDBsum; 1XWD; -. DR PDBsum; 4AY9; -. DR PDBsum; 4MQW; -. DR PDBsum; 8I2G; -. DR PDBsum; 8I2H; -. DR AlphaFoldDB; P23945; -. DR EMDB; EMD-35135; -. DR EMDB; EMD-35136; -. DR SMR; P23945; -. DR BioGRID; 108770; 36. DR DIP; DIP-35605N; -. DR IntAct; P23945; 21. DR MINT; P23945; -. DR STRING; 9606.ENSP00000384708; -. DR BindingDB; P23945; -. DR ChEMBL; CHEMBL2024; -. DR DrugBank; DB00097; Choriogonadotropin alfa. DR DrugBank; DB09066; Corifollitropin alfa. DR DrugBank; DB00066; Follitropin. DR DrugBank; DB00032; Menotropins. DR DrugBank; DB04786; Suramin. DR DrugBank; DB00094; Urofollitropin. DR DrugCentral; P23945; -. DR GuidetoPHARMACOLOGY; 253; -. DR TCDB; 9.A.14.1.5; the g-protein-coupled receptor (gpcr) family. DR GlyCosmos; P23945; 4 sites, No reported glycans. DR GlyGen; P23945; 4 sites. DR iPTMnet; P23945; -. DR PhosphoSitePlus; P23945; -. DR BioMuta; FSHR; -. DR DMDM; 311033420; -. DR MassIVE; P23945; -. DR PaxDb; 9606-ENSP00000384708; -. DR PeptideAtlas; P23945; -. DR Antibodypedia; 15300; 838 antibodies from 36 providers. DR DNASU; 2492; -. DR Ensembl; ENST00000304421.8; ENSP00000306780.4; ENSG00000170820.12. DR GeneID; 2492; -. DR KEGG; hsa:2492; -. DR UCSC; uc002rww.4; human. DR UCSC; uc010fbn.4; human. [P23945-1] DR AGR; HGNC:3969; -. DR CTD; 2492; -. DR DisGeNET; 2492; -. DR GeneCards; FSHR; -. DR HGNC; HGNC:3969; FSHR. DR HPA; ENSG00000170820; Group enriched (ovary, testis). DR MalaCards; FSHR; -. DR MIM; 136435; gene. DR MIM; 233300; phenotype. DR MIM; 608115; phenotype. DR neXtProt; NX_P23945; -. DR Orphanet; 243; 46,XX gonadal dysgenesis. DR Orphanet; 619; NON RARE IN EUROPE: Primary ovarian failure. DR Orphanet; 64739; Ovarian hyperstimulation syndrome. DR PharmGKB; PA28386; -. DR VEuPathDB; HostDB:ENSG00000170820; -. DR eggNOG; KOG2087; Eukaryota. DR HOGENOM; CLU_006130_1_1_1; -. DR InParanoid; P23945; -. DR OrthoDB; 1202285at2759; -. DR PhylomeDB; P23945; -. DR TreeFam; TF316814; -. DR PathwayCommons; P23945; -. DR Reactome; R-HSA-375281; Hormone ligand-binding receptors. DR Reactome; R-HSA-418555; G alpha (s) signalling events. DR SignaLink; P23945; -. DR SIGNOR; P23945; -. DR BioGRID-ORCS; 2492; 13 hits in 1153 CRISPR screens. DR ChiTaRS; FSHR; human. DR EvolutionaryTrace; P23945; -. DR GeneWiki; Follicle-stimulating_hormone_receptor; -. DR GenomeRNAi; 2492; -. DR Pharos; P23945; Tclin. DR PRO; PR:P23945; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P23945; Protein. DR Bgee; ENSG00000170820; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 72 other cell types or tissues. DR ExpressionAtlas; P23945; baseline and differential. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:UniProtKB. DR GO; GO:0004963; F:follicle-stimulating hormone receptor activity; IDA:UniProtKB. DR GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central. DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central. DR GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IMP:UniProtKB. DR GO; GO:0007292; P:female gamete generation; TAS:ProtInc. DR GO; GO:0008585; P:female gonad development; TAS:ProtInc. DR GO; GO:0042699; P:follicle-stimulating hormone signaling pathway; IDA:UniProtKB. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0008406; P:gonad development; TAS:ProtInc. DR GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central. DR GO; GO:0008584; P:male gonad development; IEP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB. DR GO; GO:0010738; P:regulation of protein kinase A signaling; IMP:UniProtKB. DR GO; GO:0007283; P:spermatogenesis; TAS:ProtInc. DR CDD; cd15360; 7tmA_FSH-R; 1. DR Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR InterPro; IPR002272; FSH_rcpt. DR InterPro; IPR024635; GnHR_TM. DR InterPro; IPR000276; GPCR_Rhodpsn. DR InterPro; IPR017452; GPCR_Rhodpsn_7TM. DR InterPro; IPR002131; Gphrmn_rcpt_fam. DR InterPro; IPR026906; LRR_5. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR000372; LRRNT. DR PANTHER; PTHR24372:SF5; FOLLICLE-STIMULATING HORMONE RECEPTOR; 1. DR PANTHER; PTHR24372; GLYCOPROTEIN HORMONE RECEPTOR; 1. DR Pfam; PF00001; 7tm_1; 1. DR Pfam; PF12369; GnHR_trans; 1. DR Pfam; PF13306; LRR_5; 2. DR Pfam; PF01462; LRRNT; 1. DR PRINTS; PR01143; FSHRECEPTOR. DR PRINTS; PR00373; GLYCHORMONER. DR PRINTS; PR00237; GPCRRHODOPSN. DR SMART; SM00013; LRRNT; 1. DR SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1. DR SUPFAM; SSF52058; L domain-like; 1. DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1. DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1. DR Genevisible; P23945; HS. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell membrane; Disease variant; KW Disulfide bond; G-protein coupled receptor; Glycoprotein; KW Leucine-rich repeat; Membrane; Receptor; Reference proteome; Repeat; KW Signal; Sulfation; Transducer; Transmembrane; Transmembrane helix. FT SIGNAL 1..17 FT /evidence="ECO:0000255" FT CHAIN 18..695 FT /note="Follicle-stimulating hormone receptor" FT /id="PRO_0000012771" FT TOPO_DOM 18..366 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 367..387 FT /note="Helical; Name=1" FT /evidence="ECO:0000255" FT TOPO_DOM 388..398 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 399..421 FT /note="Helical; Name=2" FT /evidence="ECO:0000255" FT TOPO_DOM 422..443 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 444..465 FT /note="Helical; Name=3" FT /evidence="ECO:0000255" FT TOPO_DOM 466..485 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 486..508 FT /note="Helical; Name=4" FT /evidence="ECO:0000255" FT TOPO_DOM 509..528 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 529..550 FT /note="Helical; Name=5" FT /evidence="ECO:0000255" FT TOPO_DOM 551..573 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 574..597 FT /note="Helical; Name=6" FT /evidence="ECO:0000255" FT TOPO_DOM 598..608 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 609..630 FT /note="Helical; Name=7" FT /evidence="ECO:0000255" FT TOPO_DOM 631..695 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 18..46 FT /note="LRRNT" FT REPEAT 49..72 FT /note="LRR 1" FT REPEAT 73..97 FT /note="LRR 2" FT REPEAT 98..118 FT /note="LRR 3" FT REPEAT 119..143 FT /note="LRR 4" FT REPEAT 144..169 FT /note="LRR 5" FT REPEAT 170..192 FT /note="LRR 6" FT REPEAT 193..216 FT /note="LRR 7" FT REPEAT 217..240 FT /note="LRR 8" FT REPEAT 241..259 FT /note="LRR 9" FT MOD_RES 335 FT /note="Sulfotyrosine" FT /evidence="ECO:0000305|PubMed:11847099" FT CARBOHYD 191 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15662415, FT ECO:0000269|PubMed:24692546, ECO:0007744|PDB:4MQW" FT CARBOHYD 199 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 293 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000250" FT CARBOHYD 318 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 18..25 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00521, FT ECO:0000269|PubMed:15662415, ECO:0000269|PubMed:24692546, FT ECO:0007744|PDB:4MQW" FT DISULFID 23..32 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00521, FT ECO:0000269|PubMed:15662415, ECO:0000269|PubMed:24692546, FT ECO:0007744|PDB:4MQW" FT DISULFID 275..346 FT /evidence="ECO:0000269|PubMed:24692546, FT ECO:0007744|PDB:4MQW" FT DISULFID 276..356 FT /evidence="ECO:0000269|PubMed:24692546, FT ECO:0007744|PDB:4MQW" FT DISULFID 276..292 FT /evidence="ECO:0000269|PubMed:24692546, FT ECO:0007744|PDB:4MQW" FT DISULFID 292..338 FT /evidence="ECO:0000269|PubMed:24692546, FT ECO:0007744|PDB:4MQW" FT DISULFID 442..517 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00521" FT VAR_SEQ 149..174 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_043181" FT VAR_SEQ 223 FT /note="L -> LNRRTRTPTEPNVLLAKYPSGQGVLEEPESLSSSI (in isoform FT 4)" FT /evidence="ECO:0000305" FT /id="VSP_053411" FT VAR_SEQ 224..285 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:1359889" FT /id="VSP_001953" FT VARIANT 128 FT /note="S -> Y (in OHSS; displays increase in affinity and FT sensitivity toward hCG and does not show any constitutive FT activity nor promiscuous activation by TSH; FT dbSNP:rs121909665)" FT /evidence="ECO:0000269|PubMed:17721928" FT /id="VAR_039279" FT VARIANT 160 FT /note="I -> T (in ODG1; impairs cell surface expression)" FT /evidence="ECO:0000269|PubMed:9769327" FT /id="VAR_018045" FT VARIANT 189 FT /note="A -> V (in ODG1; very frequent in the Finnish FT population)" FT /evidence="ECO:0000269|PubMed:7553856, FT ECO:0000269|PubMed:9851774" FT /id="VAR_018046" FT VARIANT 224 FT /note="D -> V (in ODG1; FSH binding is barely detectable; FT impaired targeting to the cell membrane; adenylate cyclase FT stimulation by FSH is 4 +-2% residual activity)" FT /evidence="ECO:0000269|PubMed:10551778" FT /id="VAR_039280" FT VARIANT 307 FT /note="A -> T (in dbSNP:rs6165)" FT /evidence="ECO:0000269|PubMed:10391209, FT ECO:0000269|PubMed:12059813, ECO:0000269|PubMed:1301382, FT ECO:0000269|PubMed:1322283, ECO:0000269|PubMed:1359889, FT ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:7916967, ECO:0000269|Ref.5" FT /id="VAR_013903" FT VARIANT 348 FT /note="P -> R (in ODG1)" FT /evidence="ECO:0000269|PubMed:12571157" FT /id="VAR_039281" FT VARIANT 419 FT /note="A -> T (in ODG1)" FT /evidence="ECO:0000269|PubMed:11889179" FT /id="VAR_018047" FT VARIANT 449 FT /note="T -> A (in OHSS; increase of receptor sensitivity to FT both hCG and TSH together with an increase in basal FT activity)" FT /evidence="ECO:0000269|PubMed:15080154" FT /id="VAR_039282" FT VARIANT 449 FT /note="T -> I (in OHSS; dbSNP:rs28928870)" FT /evidence="ECO:0000269|PubMed:12930927" FT /id="VAR_017244" FT VARIANT 512 FT /note="M -> I (in OHSS; inhibits activation of PI3K/AKT FT signaling pathway; reduces cAMP production; no effect on FT ERK1/2 signaling pathway activation)" FT /evidence="ECO:0000269|PubMed:24058690" FT /id="VAR_074535" FT VARIANT 514 FT /note="V -> A (in OHSS; increases cell surface expression; FT no effect on hormone binding; increases signaling FT activity)" FT /evidence="ECO:0000269|PubMed:25581598" FT /id="VAR_074536" FT VARIANT 519 FT /note="P -> T (in ODG1; totally impairs adenylate cyclase FT stimulation in vitro; alters the cell surface targeting of FT the receptor which remains trapped intracellularly)" FT /evidence="ECO:0000269|PubMed:12915623" FT /id="VAR_039283" FT VARIANT 524 FT /note="S -> R (in dbSNP:rs6167)" FT /evidence="ECO:0000269|PubMed:10391209" FT /id="VAR_013904" FT VARIANT 545 FT /note="I -> T (in OHSS; displays promiscuous activation by FT both hCG and TSH together with detectable constitutive FT activity)" FT /evidence="ECO:0000269|PubMed:16278261" FT /id="VAR_039284" FT VARIANT 567 FT /note="D -> G (activating mutation resulting in 1.5-fold FT increase in basal cAMP production compared to the wild-type FT receptor)" FT /evidence="ECO:0000269|PubMed:8636335" FT /id="VAR_039285" FT VARIANT 567 FT /note="D -> N (in OHSS; dbSNP:rs28928871)" FT /evidence="ECO:0000269|PubMed:12930928" FT /id="VAR_017245" FT VARIANT 573 FT /note="R -> C (in ODG1; alters signal transduction of the FT receptor; adenylate cyclase stimulation by FSH is 24 +-4% FT residual activity)" FT /evidence="ECO:0000269|PubMed:10551778, FT ECO:0000269|PubMed:9769327" FT /id="VAR_018048" FT VARIANT 575 FT /note="A -> V (in OHSS; decreases cell surface expression; FT no effect on hormone binding; increases levels of FT internalized hormone receptor complex; cAMP levels are FT similar to basal levels even at high doses of FSH FT stimulation indicating reduced signaling)" FT /evidence="ECO:0000269|PubMed:25581598" FT /id="VAR_074537" FT VARIANT 591 FT /note="F -> S (in ovarian sex cord tumor; loss of FT function)" FT /evidence="ECO:0000269|PubMed:9100567" FT /id="VAR_018049" FT VARIANT 601 FT /note="L -> V (in ODG1; binds FSH with a similar affinity FT than the wild-type receptor; adenylate cyclase stimulation FT by FSH is 12 +-3% residual activity)" FT /evidence="ECO:0000269|PubMed:10551778" FT /id="VAR_039286" FT VARIANT 680 FT /note="N -> S (in dbSNP:rs6166)" FT /evidence="ECO:0000269|PubMed:10391209, FT ECO:0000269|PubMed:12059813, ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:15815621, ECO:0000269|PubMed:1709010, FT ECO:0000269|PubMed:7916967, ECO:0000269|Ref.8" FT /id="VAR_013905" FT MUTAGEN 330 FT /note="Y->F: No change in intracellular cAMP accumulation." FT /evidence="ECO:0000269|PubMed:11847099" FT MUTAGEN 335 FT /note="Y->F: Reduces intracellular cAMP accumulation." FT /evidence="ECO:0000269|PubMed:11847099" FT CONFLICT 13 FT /note="S -> R (in Ref. 10; CAA48179)" FT /evidence="ECO:0000305" FT CONFLICT 112 FT /note="N -> T (in Ref. 1; AAA52477)" FT /evidence="ECO:0000305" FT CONFLICT 197..198 FT /note="EL -> AV (in Ref. 1; AAA52477)" FT /evidence="ECO:0000305" FT CONFLICT 295 FT /note="S -> P (in Ref. 10; CAA48179)" FT /evidence="ECO:0000305" FT STRAND 21..26 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 29..34 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 49..55 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 59..61 FT /evidence="ECO:0007829|PDB:4AY9" FT TURN 63..68 FT /evidence="ECO:0007829|PDB:8I2G" FT STRAND 74..78 FT /evidence="ECO:0007829|PDB:4AY9" FT TURN 88..90 FT /evidence="ECO:0007829|PDB:4MQW" FT STRAND 99..105 FT /evidence="ECO:0007829|PDB:4AY9" FT HELIX 113..115 FT /evidence="ECO:0007829|PDB:8I2G" FT STRAND 124..130 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 143..145 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 147..153 FT /evidence="ECO:0007829|PDB:4AY9" FT TURN 162..167 FT /evidence="ECO:0007829|PDB:8I2G" FT STRAND 168..171 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 173..176 FT /evidence="ECO:0007829|PDB:4AY9" FT TURN 187..192 FT /evidence="ECO:0007829|PDB:8I2G" FT STRAND 193..199 FT /evidence="ECO:0007829|PDB:4AY9" FT TURN 211..216 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 221..224 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 235..237 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 243..245 FT /evidence="ECO:0007829|PDB:4AY9" FT TURN 258..260 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 266..268 FT /evidence="ECO:0007829|PDB:4AY9" FT HELIX 272..280 FT /evidence="ECO:0007829|PDB:4AY9" FT HELIX 290..293 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 333..335 FT /evidence="ECO:0007829|PDB:8I2G" FT STRAND 345..348 FT /evidence="ECO:0007829|PDB:4AY9" FT STRAND 351..353 FT /evidence="ECO:0007829|PDB:4MQW" FT STRAND 359..362 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 363..389 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 396..424 FT /evidence="ECO:0007829|PDB:8I2G" FT TURN 425..427 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 429..438 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 440..472 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 477..479 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 483..502 FT /evidence="ECO:0007829|PDB:8I2G" FT TURN 503..507 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 525..556 FT /evidence="ECO:0007829|PDB:8I2G" FT TURN 559..561 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 564..596 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 604..614 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 616..626 FT /evidence="ECO:0007829|PDB:8I2G" FT TURN 627..629 FT /evidence="ECO:0007829|PDB:8I2G" FT HELIX 631..643 FT /evidence="ECO:0007829|PDB:8I2G" SQ SEQUENCE 695 AA; 78265 MW; 766BC421014CD5A4 CRC64; MALLLVSLLA FLSLGSGCHH RICHCSNRVF LCQESKVTEI PSDLPRNAIE LRFVLTKLRV IQKGAFSGFG DLEKIEISQN DVLEVIEADV FSNLPKLHEI RIEKANNLLY INPEAFQNLP NLQYLLISNT GIKHLPDVHK IHSLQKVLLD IQDNINIHTI ERNSFVGLSF ESVILWLNKN GIQEIHNCAF NGTQLDELNL SDNNNLEELP NDVFHGASGP VILDISRTRI HSLPSYGLEN LKKLRARSTY NLKKLPTLEK LVALMEASLT YPSHCCAFAN WRRQISELHP ICNKSILRQE VDYMTQARGQ RSSLAEDNES SYSRGFDMTY TEFDYDLCNE VVDVTCSPKP DAFNPCEDIM GYNILRVLIW FISILAITGN IIVLVILTTS QYKLTVPRFL MCNLAFADLC IGIYLLLIAS VDIHTKSQYH NYAIDWQTGA GCDAAGFFTV FASELSVYTL TAITLERWHT ITHAMQLDCK VQLRHAASVM VMGWIFAFAA ALFPIFGISS YMKVSICLPM DIDSPLSQLY VMSLLVLNVL AFVVICGCYI HIYLTVRNPN IVSSSSDTRI AKRMAMLIFT DFLCMAPISF FAISASLKVP LITVSKAKIL LVLFHPINSC ANPFLYAIFT KNFRRDFFIL LSKCGCYEMQ AQIYRTETSS TVHNTHPRNG HCSSAPRVTN GSTYILVPLS HLAQN //